Suppr超能文献

高 Mallampati 评分与儿科程序镇静和镇痛期间更多不良事件无关。

Higher Mallampati Scores Are Not Associated with More Adverse Events During Pediatric Procedural Sedation and Analgesia.

机构信息

The Ohio State University College of Medicine/Nationwide Children's Hospital, Department of Pediatrics, Section of Emergency Medicine, Columbus, Ohio.

Children's Hospital of Pittsburgh of UPMC, Department of Pediatrics, Division of Pediatric Emergency Medicine, Pittsburgh, Pennsylvania.

出版信息

West J Emerg Med. 2018 Mar;19(2):430-436. doi: 10.5811/westjem.2017.11.35913. Epub 2018 Feb 26.

Abstract

INTRODUCTION

Procedural sedation and analgesia (PSA) is used by non-anesthesiologists (NAs) outside of the operating room for several types of procedures. Adverse events during pediatric PSA that pose the most risk to patient safety involve airway compromise. Higher Mallampati scores may indirectly indicate children at risk for airway compromise. Medical governing bodies have proposed guidelines for PSA performed by NAs, but these recommendations rarely suggest using Mallampati scores in pre-PSA evaluations. Our objective was to compare rates of adverse events during pediatric PSA in children with Mallampati scores of III/IV vs. scores of Mallampati I/II.

METHODS

This was a prospective, observational study. Children 18 years of age and under who presented to the pediatric emergency department (PED) and required PSA were enrolled. We obtained Mallampati scores as part of pre-PSA assessments. We defined adverse events as oxygen desaturation < 90%, apnea, laryngospasm, bag-valve-mask ventilation performed, repositioning of patient, emesis, and "other." We used chi-square analysis to compare rates of adverse events between groups.

RESULTS

We enrolled 575 patients. The median age of the patients was 6.0 years (interquartile range = 3.1,9.9). The primary reasons for PSA was fracture reduction (n=265, 46.1%). Most sedations involved the use of ketamine (n= 568, 98.8%). Patients with Mallampati scores of III/IV were more likely to need repositioning compared to those with Mallampati scores of I/II (p=0.049). Overall, patients with Mallampati III/IV scores did not experience a higher proportion of adverse events compared to those with Mallampati scores of I/II. The relative risk of any adverse event in patients with Mallampati scores of III/IV (40 [23.8%]) compared to patients with Mallampati scores of I/II (53 [18.3%]) was 1.3 (95% confidence interval [0.91-1.87]).

CONCLUSION

Patients with Mallampati scores of III/IV vs. Mallampati scores of I/II are not at an increased risk of adverse events during pediatric PSA. However, patients with Mallampati III/IV scores showed an increased need for repositioning, suggesting that the sedating physician should be vigilant when performing PSA in children with higher Mallampati scores.

摘要

简介

非麻醉医师在手术室外为多种类型的手术进行程序性镇静和镇痛(PSA)。儿科 PSA 期间对患者安全构成最大风险的不良事件涉及气道阻塞。较高的马兰巴蒂评分可能间接表明儿童有气道阻塞的风险。医疗管理机构已为非麻醉医师进行 PSA 提出了指南,但这些建议很少建议在 PSA 前评估中使用马兰巴蒂评分。我们的目的是比较马兰巴蒂评分 III/IV 与 I/II 评分的儿童在儿科 PSA 期间不良事件的发生率。

方法

这是一项前瞻性观察性研究。入组了在儿科急诊部(PED)就诊并需要 PSA 的 18 岁及以下的儿童。我们在 PSA 前评估中获得了马兰巴蒂评分。我们将不良事件定义为血氧饱和度<90%、呼吸暂停、喉痉挛、进行球囊面罩通气、重新定位患者、呕吐和“其他”。我们使用卡方分析比较组间不良事件发生率。

结果

我们共入组了 575 名患者。患者的中位年龄为 6.0 岁(四分位距=3.1,9.9)。PSA 的主要原因是骨折复位(n=265,46.1%)。大多数镇静涉及使用氯胺酮(n=568,98.8%)。马兰巴蒂评分 III/IV 的患者比马兰巴蒂评分 I/II 的患者更需要重新定位(p=0.049)。总体而言,马兰巴蒂 III/IV 评分的患者与马兰巴蒂 I/II 评分的患者相比,不良事件的比例没有更高。马兰巴蒂评分 III/IV(40[23.8%])的患者发生任何不良事件的相对风险与马兰巴蒂评分 I/II(53[18.3%])的患者相比为 1.3(95%置信区间[0.91-1.87])。

结论

马兰巴蒂评分 III/IV 与马兰巴蒂评分 I/II 的患者在儿科 PSA 期间不良事件的风险没有增加。然而,马兰巴蒂 III/IV 评分的患者需要重新定位的比例增加,这表明在马兰巴蒂评分较高的儿童中进行 PSA 时,镇静医师应保持警惕。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f8be/5851522/4ee2f7c903b5/wjem-19-430-s001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验